Compare Strategy Inc. (MSTR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs 10X Genomics Inc — how do they compare? Strategy Inc. trades at $156.55 (market cap $60.40B), while 10X Genomics Inc trades at $81.89 (market cap $10.07B). The key difference: Strategy Inc. is far larger — about 6× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and 10X Genomics Inc for 92 Days on average.
| MSTR | TXG | |
|---|---|---|
Market Cap | $60.40B | $10.07B |
Volume | 23,421,830 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $320.29 | $97.74 |
52-Week Low | $82.31 | $11.48 |
Typical Hold Time | 112 Days | 92 Days |
Enterprise Value | $79.16B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $151.89, down 0.96% on the day, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with a net income margin of -6,102.96% and three consecutive quarterly earnings misses. Despite negative profitability, analyst consensus remains bullish with a $253.36 price target, representing 67% upside potential from current levels. Recent news highlights Citigroup doubling its price target to $240 following a 35% monthly rally.
The outlook remains polarized between technical optimism and fundamental challenges. While technical indicators suggest continued momentum, the company's massive losses and negative cash flow from operations pose significant risks. Investors face the dilemma of strong Wall Street support against deteriorating financial performance, with the stock's fate closely tied to Bitcoin market movements despite being a traditional software company.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
